Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong (China) *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

img-spleen-targeted-neoantigen-dna-vaccine-personalized-immunotherapy-hepatocellular-carcinoma-1920x640

Literature - Publication Review

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Researchers investigated how a spleen-targeted DNA vaccine, delivered via RBC-hitchhiked nanoparticles, effectively induced robust neoantigen specific T cell responses in hepatocellular carcinoma (HCC). This approach not only inhibited tumor growth, but also showed potential for complete tumor regression when combined with anti-PD-1 therapy, offering a promising strategy for personalized immunotherapy in HCC.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

営業担当者から連絡を受けることに同意します。

お名前（名）

お名前（姓）

国

メールアドレス

会社名

郵便番号

勤務先電話番号

職種

* が付いているフィールドは入力必須です
お客様は個人データを送信することにより、Revvity Inc. およびその関連会社（以下「当社」）が、当社のプライバシーポリシー（ご覧になるにはこちらをクリック）に従って上記で提供されたお客様の個人データを処理することに同意するものとします。

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Download Literature - Publication Review